Ubs Group Ag Kal Vista Pharmaceuticals, Inc. Transaction History
Ubs Group Ag
- $582 Billion
- Q4 2025
A detailed history of Ubs Group Ag transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 371,993 shares of KALV stock, worth $4.95 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
371,993
Previous 454,148
18.09%
Holding current value
$4.95 Million
Previous $5.49 Million
9.7%
% of portfolio
0.0%
Previous 0.0%
Shares
36 transactions
Others Institutions Holding KALV
# of Institutions
158Shares Held
58MCall Options Held
1.21MPut Options Held
865K-
Vr Adviser, LLC New York, NY6.73MShares$89.6 Million12.35% of portfolio
-
Tang Capital Management LLC San Diego, CA5.04MShares$67.2 Million2.77% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.04MShares$67.1 Million2.57% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.77MShares$63.5 Million1.73% of portfolio
-
Capital World Investors Los Angeles, CA3.18MShares$42.3 Million0.01% of portfolio
About KalVista Pharmaceuticals, Inc.
- Ticker KALV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,602,000
- Market Cap $328M
- Description
- KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...